Amnion

Ashlee Morgan Scholarship for Healthcare Students: Nurturing Passion and Innovation in Healthcare Education

Retrieved on: 
Thursday, February 29, 2024
Interest, Medicine, Knowledge, B cell, Amnion, Science, Regenerative medicine, Patient, Student, Nursing

This scholarship, administered by Ashlee Morgan , a certified tissue banking specialist with over a decade of experience, takes a unique approach to healthcare education.

Key Points: 
  • This scholarship, administered by Ashlee Morgan , a certified tissue banking specialist with over a decade of experience, takes a unique approach to healthcare education.
  • To be eligible for the Ashlee Morgan Scholarship for Healthcare Students, applicants must be current undergraduate or graduate students pursuing a degree in a healthcare-related field.
  • The Ashlee Morgan Scholarship for Healthcare Students represents a commitment to nurturing the future leaders and innovators in healthcare.
  • By recognizing excellence, passion, and innovation, Ashlee Morgan aims to contribute to the evolution of medicine and improve lives.

RENOVŌ® EQUINE ALLOGRAFT WILL SHOWCASE DURING THE 2023 AAEP ANNUAL CONVENTION

Retrieved on: 
Wednesday, November 15, 2023
Momentum, EAS, DRS, Amnion, Tissue, History, Intramuscular injection, DVM, AAEP, Horse, Joint, Medical imaging, Phoenix

ARGYLE, Texas, Nov. 15, 2023 /PRNewswire/ -- Equine Amnio Solutions, LLC (EAS), distributor of the RenoVō® advanced equine allograft, announced today that the product will feature prominently during the 69th Annual Convention of the American Association of Equine Practitioners (AAEP), San Diego, CA held November 29 to December 3, 2023.

Key Points: 
  • ARGYLE, Texas, Nov. 15, 2023 /PRNewswire/ -- Equine Amnio Solutions, LLC (EAS), distributor of the RenoVō® advanced equine allograft, announced today that the product will feature prominently during the 69th Annual Convention of the American Association of Equine Practitioners (AAEP), San Diego, CA held November 29 to December 3, 2023.
  • Danica Wolkowski, DVM of Momentum Equine Veterinary Specialists, Sherwood Park, Alberta, Canada, will present compelling RenoVō® clinical data on Friday, December 1 at 8:40 am in a presentation titled, "Effects of Intra-Articular Injection of an Acellular Equine Liquid Amniotic Allograft in Healthy Equine Joints."
  • Studies establish the product as a safe and highly effective alternative to other modalities in the clinical care of equine tissue injuries.
  • RenoVō® is manufactured by Equus Innovations (Phoenix, Arizona) and has been used in over 17,000 horses to date.

BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results

Retrieved on: 
Tuesday, November 15, 2022
Marketing, Growth, Holocene, Adjustment, OTC, EDT, EBITDA, Volume Five, Conference, Corporation, MAC, Regenerative medicine, Amnion, Cytokine, Novita (company), CPA, Medicare, GAAP, Conference call, Investment, Audit committee, Renewable energy, Management, Pharmaceutical industry, Video game, Air cargo, Webcast, Noridian Mutual Insurance Company

POMPANO BEACH, FLORIDA., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • Company to Host a Conference Call and Webcast on November 15, 2022, at 4:30 pm EDT
    POMPANO BEACH, FLORIDA., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2022.
  • Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, Over the third quarter, we have continued to build on the strengths of our growth strategy.
  • Net revenue of $1.145 million for quarter ended September 30, 2022, down 13%, compared to net revenue of $1.313 million for the quarter ended September 30, 2021.
  • Quarter and Year-to Date ending September 30, 2022 Results:
    The following table represents net revenue, gross margin, operating expenses, and other income (loss) for the three and Nine-months ended September 30, 2022, and September 30, 2021, respectively:
    Three months ended September 30,
    Nine months ended September 30,

MIMEDX Announces Launch of AMNIOEFFECT™

Retrieved on: 
Monday, September 19, 2022
Debridement, ECM, Sterilization, Engineering, Suture, Amnion, Health, Growth, Blood vessel, Granulation tissue, Patient, LMR, Physician, Extracellular matrix, Allotransplantation, Tissue, Surgeon, Surgical incision, GLOBE, Placenta, Good tissue practice, 3D printing, Dentistry, Medical imaging

MARIETTA, Ga., Sept. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the launch of AMNIOEFFECT™, a tri-layer PURION® processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.

Key Points: 
  • MARIETTA, Ga., Sept. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced the launch of AMNIOEFFECT, a tri-layer PURION processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.
  • During the Limited Market Release (LMR) phase, AMNIOEFFECT was used in over 50 surgical cases.
  • The Surgical Recovery market is an engine of growth for MIMEDX, said Rohit Kashyap, Ph.D., MIMEDX President, Wound Care & Surgical.
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.

BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts

Retrieved on: 
Tuesday, September 13, 2022
Public sector banks in India, Cytokine, COVID-19, Histology, FDA, Amnion, Principal, AATB, Company, Private Securities Litigation Reform Act, American Association, Chorion, Volume Five, Forward-looking statement, American Association of Tissue Banks, Physician, OTC, Allotransplantation, Association, GLOBE, History of decompression research and development, Placenta, Regenerative medicine, Pharmaceutical industry, Medical imaging, Research

POMPANO BEACH, FLORIDA., Sept. 13, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived tissue allografts, today announced the publication of a guidance paper on growth factor standardization in a recent open-access article in Health Science Reports. The publication, titled “Standardized reporting of amnion and amnion/chorion allograft data for wound care,” was included in Volume 5, Issue 5 of Health Science Reports.

Key Points: 
  • The study investigates a standardized method to quantify the elution of growth factors and cytokines in BioStems dehydrated amniotic membrane (Vendaje) and dehydrated amnion/chorion (Vendaje AC) placental derived allografts as a function of surface (cm2).
  • BioRetain is BioStems unique tissue processing technique intended to isolate and process amnion and amnion with chorion from the placenta while preserving growth factors and tissue structure.
  • The data from this publication validate the ability of our proprietary tissue processing method, BioRetain, to maintain structural components with significant quantities of growth factors and cytokines from placental tissue.
  • Exploring the therapeutic potential and benefit of tissue allografts requires standardization of the quantification of the growth factors.

Global Amniotic Membrane Markets Report 2022-2027: A Moderately Competitive Market Featuring Stryker, Smith & Nephew, Integra LifeSciences, Wright Medical Group, MiMedx, Organogenesis Net - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Health, Biotechnology, Sepsis, Leg, Awareness, Pressure, Patient, AM, Trauma, Education, Burns, Incidence, Insight, COVID-19, Membrane, Amnion, OPDS, Cryopreservation, Hospital, Adoption, CAGR, Regenerative medicine, Research, Placenta, Risk, Health, Burn, Government, Inflammation, Infection, Ulcer, Scar, Renewable energy, Pet, Dentistry, Health insurance, Growth

The use of an amniotic membrane is preferred due to its anti-scarring property, non-immunogenicity, antimicrobial property, and ability to reduce inflammation.

Key Points: 
  • The use of an amniotic membrane is preferred due to its anti-scarring property, non-immunogenicity, antimicrobial property, and ability to reduce inflammation.
  • However, the amniotic membrane is expected to exhibit significant market growth during the forecast period, owing to technological innovations to develop cost-effective therapies.
  • The rise in amniotic membrane transplantation, awareness and education about the benefits of amniotic membrane transplantation, and the growth of the geriatric population propel the market growth.
  • Based on type, Amniotic Membrane includes Cryopreserved amniotic membranes and Dehydrated Amniotic Membranes.

AlphaLogix announces market release of AlphaFlo® canine allograft

Retrieved on: 
Thursday, March 31, 2022
Endless Renovation, Multimedia, USP, Live birth, Tissue, Health, View, LLC, Equus, EAS, Dog, Animal, Allotransplantation, Amnion, Patient, Partnership, Vaccine, MD, Phoenix

PHOENIX, March 31, 2022 /PRNewswire/ -- Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo.

Key Points: 
  • PHOENIX, March 31, 2022 /PRNewswire/ -- Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo.
  • AlphaFlo is a liquid, acellular, canine amniotic tissue allograft comprised of amnion, intended to supplement and protect tissues.
  • Grant D. Senner, MD, DABRM and Equus Innovations' Chief Executive Officer stated, "The release of AlphaFlo by AlphaLogix is another exciting regenerative solution for veterinary patients.
  • AlphaLogix, LLC is a leading provider of next-generation canine veterinary products, including AlphaFlo.

Study in Modern Optometry Shows Effectiveness Of Merakris Therapeutics’ Eye Product, Opticyte® Matrix

Retrieved on: 
Thursday, March 24, 2022
Private Securities Litigation Reform Act, Therapy, Marketing, Forward-looking statement, Patient, PARK, Biotechnology, Research, Wound healing, Research Triangle, Research Triangle Park, Punctate epithelial erosions, Safety, Cornea, RESEARCH, Placenta, Intellectual property, Regulation, GLOBE, Optometry, Duane syndrome, MIS, Amnion, History, Mother, Cosmetics, Medical imaging, Pharmaceutical industry

Merakris said Opticyte Matrix also supports cell attachment and ingrowth and is commonly used as a supplemental protective barrier in patients with dry eye disease and other corneal defects.

Key Points: 
  • Merakris said Opticyte Matrix also supports cell attachment and ingrowth and is commonly used as a supplemental protective barrier in patients with dry eye disease and other corneal defects.
  • The latest edition of Modern Optometry highlights the study of a patient with a history of treatment-resistant severe dry eye disease, filamentary keratitis and epithelial erosions whose symptoms were resolved through the use of Opticyte Matrix in combination with other therapies.
  • The use of amniotic membrane technologies is being used more frequently to treat nonhealing corneal defects, according to the study.
  • The case report featured in Modern Optometry provides further evidence of the effectiveness of Opticyte Matrix as a potential treatment for a variety of debilitating and potentially serious eye problems, said Merakris CEO Chris Broderick.

ESSENT BIOLOGICS AND AMNION FOUNDATION PARTNER TO PROVIDE GERMINAL-ORIGIN CELLS TO FURTHER DRUG DISCOVERY AND REGENERATIVE MEDICINE RESEARCH

Retrieved on: 
Tuesday, December 14, 2021
Amnion, Method, Regenerative medicine, Blood, Government, Cytotrophoblast, Infection, Child, Cell, Adult, Umbilical cord, Toxicology, PSC, Research, Biotechnology, Safety, Good manufacturing practice, Cord blood, CGMP, Drug development, Agricultural Research Service, CTBS, Multimedia, Placenta, Partnership, GMP, Foundation, Zika virus, Hofbauer cell, View, Pharmaceutical industry, Fine chemical, Vaccine, Essent, Hofbauer

This distribution agreement marks the first time that several unique cell types - cytotrophoblasts, Hofbauer cells, and placental stem/stromal cells - have been made commercially available worldwide for use in regenerative medicine, toxicology, and drug development.

Key Points: 
  • This distribution agreement marks the first time that several unique cell types - cytotrophoblasts, Hofbauer cells, and placental stem/stromal cells - have been made commercially available worldwide for use in regenerative medicine, toxicology, and drug development.
  • "We are thrilled to work with the team at Essent to get our unique cells in the hands of leading researchers discovering and developing new in vitro models and regenerative medicine products."
  • The PSCs, backed by over two decades of peer-reviewed scientific publications, are now available to support research in regenerative medicine.
  • The nonprofit biotechnology company provides low-passaged primary cells, research tissue and scaffold materials to advance regenerative medicine research from benchtop to bedside.

LifeNet Health features powerful biologics to support wound healing at SAWC Fall

Retrieved on: 
Thursday, October 28, 2021
Science, Amy Compton-Phillips, Technology, DPM, Innovation, Patient, Mechanics, SAWC, PLOS One, Decellularization, Face, Chorion, Amnion, Multimedia, Regenerative medicine, Solution, Health, Publication, New York Innovative Theatre Awards, Regeneration, Physician, Medicine, Medical imaging, Mobile phone

LAS VEGAS, Oct. 28, 2021 /PRNewswire/ -- LifeNet Health, the world's leading provider of allograft biologics, is showcasing its unique allograft solutions for wounds at the 2021 Symposium on Advanced Wound Care (SAWC) Fall meeting Oct. 29-31 in Las Vegas.

Key Points: 
  • LAS VEGAS, Oct. 28, 2021 /PRNewswire/ -- LifeNet Health, the world's leading provider of allograft biologics, is showcasing its unique allograft solutions for wounds at the 2021 Symposium on Advanced Wound Care (SAWC) Fall meeting Oct. 29-31 in Las Vegas.
  • "LifeNet Health's wound solutions help physicians take patient care to the next level by solving clinical challenges they face every day," said Mike Falcon, Vice President of Wound Management and Surgical Reconstruction.
  • "With Matrion and Dermacell AWM, we're providing the most advanced allograft biologics available for treating both commonplace and complex wounds."
  • LifeNet Health helps save lives, restore health, and give hope to thousands each year.